Profile data is unavailable for this security.
About the company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
- Revenue in EUR (TTM)7.52bn
- Net income in EUR372.72m
- Incorporated1987
- Employees23.83k
- LocationGrifols SAParque Empresarial Can Sant JoanAvinguda de la Generalitat, 152-158SANT CUGAT DEL VALLES 08174SpainESP
- Phone+34 935712200
- Fax+34 938008000
- Websitehttps://www.grifols.com/
More ▼
Mergers & acquisitions
| Acquired company | GRF:MCE since announced | Transaction value |
|---|---|---|
| Immunotek Biocenters LLC-Plasma Centers(6) | 0.09% | 62.42m |
Data delayed at least 15 minutes, as of Feb 27 2026 16:42 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Richter Gedeon Vegyeszeti Gyar Nyrt | 2.47bn | 616.59m | 5.91bn | 11.76k | 9.39 | 1.53 | 7.60 | 2.40 | 1,271.00 | 1,271.00 | 5,079.90 | 7,796.99 | 0.5657 | 1.34 | 3.72 | -- | 14.14 | 13.93 | 15.84 | 15.72 | 68.99 | 63.32 | 25.00 | 23.46 | 3.26 | 35.87 | 0.0149 | -- | 8.33 | 10.39 | -2.89 | 17.29 | -0.0703 | -- |
| ALK-Abello A/S | 844.74m | 160.19m | 5.97bn | 2.72k | 40.84 | 7.58 | 29.47 | 7.07 | 5.40 | 5.40 | 28.47 | 29.09 | 0.7296 | 1.19 | 6.63 | 2,319,736.00 | 13.84 | 8.87 | 17.07 | 11.22 | 67.08 | 63.78 | 18.96 | 12.16 | 2.04 | 87.05 | 0.0609 | 11.63 | 14.00 | 12.58 | 46.87 | 116.79 | 10.15 | -- |
| 3SBio Inc | 1.12bn | 291.85m | 6.03bn | 6.27k | 20.08 | 2.77 | 16.56 | 5.37 | 1.09 | 1.09 | 4.20 | 7.91 | 0.3799 | 1.54 | 6.97 | 1,860,650.00 | 10.46 | 7.95 | 15.09 | 10.32 | 85.37 | 83.73 | 27.54 | 22.68 | 2.12 | -- | 0.0899 | -- | 16.53 | 11.36 | 34.93 | 16.51 | 14.65 | -- |
| Alkem Laboratories Ltd | 1.32bn | 220.38m | 6.27bn | 18.64k | 28.44 | -- | 23.99 | 4.73 | 198.32 | 198.32 | 1,192.01 | -- | -- | -- | -- | 7,645,478.00 | -- | 12.12 | -- | 17.53 | 64.05 | 60.06 | 17.00 | 14.69 | -- | 18.13 | -- | 28.96 | 2.34 | 9.21 | 20.59 | 13.95 | 13.22 | 12.47 |
| Beijing Wantai Biolog Pha Ent Co Ltd | 221.62m | -41.20m | 6.40bn | 3.79k | -- | 4.29 | -- | 28.86 | -0.2438 | -0.2438 | 1.38 | 9.56 | 0.1234 | 1.11 | 0.8599 | 473,789.40 | -2.30 | 17.63 | -2.69 | 22.63 | 48.33 | 83.87 | -18.67 | 33.20 | 3.82 | -- | 0.0295 | 9.99 | -59.25 | 13.66 | -91.49 | -12.65 | 40.51 | -- |
| Grifols SA | 7.52bn | 372.72m | 6.53bn | 23.83k | 19.47 | 1.40 | 7.26 | 0.8692 | 0.546 | 0.546 | 11.02 | 7.62 | 0.3746 | 1.35 | 7.15 | 315,451.40 | 2.28 | 1.72 | 2.99 | 2.21 | 39.09 | 38.85 | 6.09 | 5.43 | 0.9283 | 2.52 | 0.5621 | -- | 9.41 | 7.18 | 270.81 | -24.15 | -2.07 | -- |
| Aurobindo Pharma Ltd | 3.08bn | 324.07m | 6.59bn | 9.11k | 20.33 | -- | 13.56 | 2.14 | 60.04 | 60.04 | 571.33 | -- | -- | -- | -- | 36,435,560.00 | -- | 8.62 | -- | 12.13 | 59.35 | 53.55 | 10.50 | 12.38 | -- | 14.24 | -- | 7.25 | 9.39 | 6.55 | 9.86 | 4.15 | 11.98 | -- |
| Krystal Biotech Inc | 329.38m | 173.38m | 6.82bn | 295.00 | 40.30 | 6.60 | 38.27 | 20.71 | 6.84 | 6.84 | 13.00 | 41.78 | 0.3257 | 0.6882 | 3.35 | 1,319,085.00 | 17.14 | 2.46 | 18.75 | 2.63 | 94.08 | -- | 52.64 | 13.06 | 9.56 | -- | 0.00 | 0.00 | 33.94 | -- | 129.74 | -- | -4.24 | -- |
| Halozyme Therapeutics, Inc. | 1.18bn | 268.23m | 6.95bn | 423.00 | 27.91 | 167.77 | 20.26 | 5.88 | 2.49 | 2.49 | 11.38 | 0.4144 | 0.6087 | 1.44 | 3.73 | 3,301,681.00 | 13.81 | 19.86 | 14.83 | 21.98 | 83.62 | 81.56 | 22.69 | 37.92 | 3.66 | -- | 0.9777 | 0.00 | 37.55 | 39.16 | -28.64 | 19.68 | 159.51 | -- |
| Axsome Therapeutics Inc | 540.45m | -155.05m | 7.10bn | 925.00 | -- | 94.45 | -- | 13.13 | -3.69 | -3.69 | 12.84 | 1.74 | 1.01 | 2.17 | 3.48 | 690,265.90 | -29.11 | -51.00 | -56.42 | -77.57 | 92.56 | -- | -28.69 | -76.38 | 1.48 | -25.78 | 0.6878 | -- | 65.55 | -- | 36.22 | -- | 59.92 | -- |
| Ono Pharmaceutical Co Ltd | 2.76bn | 338.48m | 7.23bn | 4.29k | 20.15 | 1.50 | 13.42 | 2.62 | 132.76 | 132.76 | 1,084.01 | 1,786.88 | 0.4702 | 2.14 | 3.38 | 118,811,500.00 | 5.77 | 10.78 | 6.61 | 12.37 | 69.79 | 73.23 | 12.27 | 21.23 | 2.56 | 125.26 | 0.1283 | 36.33 | -3.14 | 10.73 | -60.89 | -3.47 | -18.66 | 12.20 |
Data as of Feb 27 2026. Currency figures normalised to Grifols SA's reporting currency: Euro EUR
26.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Brandes Investment Partners LPas of 31 Dec 2025 | 23.45m | 5.50% |
| Capital Research & Management Co. (World Investors)as of 05 Feb 2025 | 14.51m | 3.41% |
| DWS Investment GmbHas of 10 Jun 2024 | 13.78m | 3.23% |
| Flat Footed LLCas of 31 Dec 2024 | 13.34m | 3.13% |
| The Vanguard Group, Inc.as of 31 Jan 2026 | 10.74m | 2.52% |
| Mason Capital Management LLCas of 31 Dec 2024 | 9.01m | 2.11% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 8.10m | 1.90% |
| Bestinver Gesti�n SA SGIICas of 31 Dec 2025 | 6.79m | 1.59% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 5.81m | 1.36% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 5.57m | 1.31% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
